Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.37 |
| ▸ | BACE1 | P56817 | 5/20 | 0.36 |
| ▸ | LPAR1 | Q92633 | 7/20 | 0.36 |
| ▸ | CFTR | P13569 | 2/20 | 0.35 |
| ▸ | LPAR3 | Q9UBY5 | 1/20 | 0.34 |
| ▸ | GRM1 | Q13255 | 2/20 | 0.33 |
| ▸ | GRM5 | P41594 | 1/20 | 0.33 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.33 |
| ▸ | KDR | P35968 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14710914 | 0.88 | LPAR1 (0.40) | LPAR1CFTRLPAR3 | |
| SCHEMBL14711103 | 0.86 | NPSR1 (0.40) | HRH3BACE1CFTR | |
| SCHEMBL14710249 | 0.78 | LPAR1 (0.38) | HRH3LPAR1LPAR3 | |
| SCHEMBL14794845 | 0.77 | NPSR1 (0.44) | HRH3LPAR1LPAR3 | |
| SCHEMBL899644 | 0.75 | BACE1 (0.52) | BACE1GRM1GRM5 | |
| SCHEMBL14711658 | 0.75 | LPAR1 (0.56) | LPAR1LPAR3 | |
| SCHEMBL12691935 | 0.74 | KDR (0.49) | PDGFRBKDR | |
| SCHEMBL14710182 | 0.74 | BACE1 (0.42) | BACE1 | |
| SCHEMBL14711123 | 0.74 | PTGS1 (0.57) | LPAR1 | |
| SCHEMBL3294243 | 0.73 | DHODH (0.43) | BACE1GRM1PDGFRBKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8975235-B2 | Lysophosphatidic acid receptor antagonists | INTERMUNE, INC. (US) | 2015-03-10 | — | — | US | disclosed |
| US-20130072449-A1 | LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | INTERMUNE, INC. (US) | 2013-03-21 | — | — | US | disclosed |
| WO-2013025733-A1 | LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | INTERMUNE, INC. (US) | 2013-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130072449-A1 | LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | LPAR1, LPAR2, LPAR5 | HRH3 140/4885BACE1 3099/4885LPAR1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.